PMID- 26497516
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20240210
IS  - 1600-065X (Electronic)
IS  - 0105-2896 (Linking)
VI  - 268
IP  - 1
DP  - 2015 Nov
TI  - FcgammaR requirements leading to successful immunotherapy.
PG  - 104-22
LID - 10.1111/imr.12342 [doi]
AB  - Monoclonal antibody (mAb) immunotherapy is currently experiencing an 
      unprecedented amount of success, delivering blockbuster sales for the 
      pharmaceutical industry. Having experienced several false dawns and overcoming 
      technical issues which limited progress, we are now entering a golden period 
      where mAbs are becoming a mainstay of treatment regimes for diseases ranging from 
      cancer to autoimmunity. In this review, we discuss how these mAbs are most likely 
      working and focus in particular on the key receptors that they interact with to 
      precipitate their therapeutic effects. Although their targets may vary, their 
      engagement with Fcgamma receptors (FcgammaRs) on numerous immune effector cells is almost 
      universal, and here we review their roles in delivering successful immunotherapy.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Dahal, Lekh N
AU  - Dahal LN
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University 
      of Southampton, General Hospital, Southampton, UK.
FAU - Roghanian, Ali
AU  - Roghanian A
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University 
      of Southampton, General Hospital, Southampton, UK.
FAU - Beers, Stephen A
AU  - Beers SA
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University 
      of Southampton, General Hospital, Southampton, UK.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University 
      of Southampton, General Hospital, Southampton, UK.
LA  - eng
GR  - 18518/CRUK_/Cancer Research UK/United Kingdom
GR  - BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Immunol Rev
JT  - Immunological reviews
JID - 7702118
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Autoimmunity
MH  - Cytotoxicity, Immunologic
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immunoglobulin G/*immunology/*metabolism
MH  - Immunomodulation
MH  - *Immunotherapy
MH  - Leukocytes/immunology/metabolism
MH  - Mice
MH  - Neoplasms/immunology/metabolism/therapy
MH  - Protein Binding
MH  - Receptors, IgG/chemistry/genetics/*metabolism
MH  - Signal Transduction
MH  - Transplantation
OTO - NOTNLM
OT  - FcgammaR
OT  - anti-CD20
OT  - antibody therapy
OT  - immunomodulation
OT  - immunotherapy
EDAT- 2015/10/27 06:00
MHDA- 2016/08/20 06:00
CRDT- 2015/10/27 06:00
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
AID - 10.1111/imr.12342 [doi]
PST - ppublish
SO  - Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342.